| Bioactivity | Orforglipron (LY3502970) (GLP-1 receptor agonist 1) is a GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67[1]. | ||||||||||||
| Target | GLP-1 receptor | ||||||||||||
| Invitro | Orforglipron is an incretin secreted from L cells of the small intestine when nutrients pass through the digestive tract, and glucose is transmitted via the GLP-1 receptor. Orforglipron exhibits various actions such as dependent gastric emptying delay, and feeding suppression[1]. | ||||||||||||
| Name | Orforglipron | ||||||||||||
| CAS | 2212020-52-3 | ||||||||||||
| Formula | C48H48F2N10O5 | ||||||||||||
| Molar Mass | 882.96 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Pyrazolopyridine derivative having glp-1 receptor agonist effect. WO2013046136A1. [2]. Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A. 2020;117(47):29959-29967. |
Orforglipron
CAS: 2212020-52-3 F: C48H48F2N10O5 W: 882.96
Orforglipron (LY3502970) (GLP-1 receptor agonist 1) is a GLP-1 receptor agonist extracted from patent WO2018056453A1, Co
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.